Milli Gupta, MD
Endocrinology, Diabetes & Metabolism · Munster, INNPI 1477831097
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,737 of the $4,372 with a category attached, or 85.5%. It is spread thinly across 32 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations.
Across 129 payments — averaging $33.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$448
- Medtronic$425
- AstraZeneca$400
- Celltrion, Inc.$350
- Insulet Corporation$241
- Abbott$234
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,73785%
- Education$2265%
- Gifts$4099%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $448 |
| Medtronic(2 entities) | 4 | $425 |
| AstraZeneca(2 entities) | 16 | $400 |
| Celltrion, Inc. | 1 | $350 |
| Insulet Corporation | 3 | $241 |
| Abbott | 6 | $234 |
| Lilly USA, LLC | 6 | $220 |
| BETA Bionics, Inc. | 2 | $209 |
| Mannkind Corporation | 9 | $199 |
| Amgen | 2 | $144 |
| Madrigal Pharmaceuticals | 2 | $140 |
| Shire North American Group Inc | 9 | $140 |
| Sequel Med Tech, LLC | 1 | $134 |
| Sanofi-aventis U.S. LLC | 8 | $127 |
| Boston Scientific | 1 | $125 |
| Cequr Corporation | 1 | $117 |
| Xeris Pharmaceuticals, Inc. | 1 | $95 |
| Amneal Pharmaceuticals LLC | 5 | $94 |
| AbbVie | 4 | $80 |
| Dexcom, Inc. | 1 | $73 |
| Antares Pharma, Inc. | 4 | $64 |
| Endo Pharmaceuticals Inc. | 3 | $60 |
| IBSA Pharma Inc. | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $36 |
| Corcept Therapeutics | 2 | $32 |
| Tandem Diabetes Care, Inc. | 2 | $31 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| BD | 1 | $21 |
| UCB, Inc. | 1 | $20 |
| Gilead | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Companion Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$408
- Stoboclo$350
- INPEN SMART INSULIN DELIVERY SYSTEM$303
- Omnipod$221
- iLet Insulin Infusion Kit Inset$136
- iLet Insulin Infusion Kit Contact Detach$136
- TWIIST$134
- WATCHMAN Access System$125
- JARDIANCE$125
- TEPEZZA$124
- REZDIFFRA$119
- CeQur Simplicity$117
- MINIMED 780G$104
How this compares
$4,372 in reported general payments places this provider in the 65th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 190 | $391,826 |
| MounjaroTirzepatide | 123 | $251,716 |
| JardianceEmpagliflozin | 77 | $119,495 |
| TrulicityDulaglutide | 50 | $93,390 |
| Tresiba Flextouch U-100Insulin Degludec | 86 | $60,418 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $59,987 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $58,543 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $42,246 |
| FarxigaDapagliflozin Propanediol | 30 | $39,090 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 17 | $27,553 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 179 | $27,333 |
| Humulin R U-500Insulin Regular, Human | 16 | $26,048 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $24,442 |
| JanuviaSitagliptin Phosphate | 15 | $24,082 |
| Humalog Kwikpen U-100Insulin Lispro | 71 | $20,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $448 | $400,460216 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog, Insulin Lispro | $220 | $360,449209 claims |
| AstraZenecaFarxiga | $400 | $39,09030 claims |
| AbbVieSynthroid | $80 | $9,748109 claims |
| Sanofi-aventis U.S. LLCLantus | $127 | $5,80433 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $94 | $4,875471 claims |
| IBSA Pharma Inc.Tirosint | $46 | $3,41624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Munster
- Sana MeahMunster$12K
- Nabeel JabriMunster$11K
- Thottathil GopanMunster$8K
- Maali MilhemMunster$5K
- Nirmal NairMunster$3K
- Ali Al KhazaaliMunster$3K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.